Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-05-08 pm EDT 5-day change 1st Jan Change
129.6 USD -0.64% Intraday chart for Merck & Co., Inc. +0.26% +18.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement MT
AstraZeneca, Merck Sue Over Cancer Drug Patent Infringement MT
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab) CI
Merck: encouraging results in gastric cancer CF
Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial MT
Redburn Atlantic Adjusts Price Target on Merck to $148 From $142 MT
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma CI
BioMed X Announces the Start of A New Research Project in Partnership with Merck CI
Merck Reports Positive Data for Investigational 21-Valent Pneumococcal Vaccine MT
Blackstone beats Concord with $1.6 bln bid for Hipgnosis Songs RE
Habeck's 'pharma trip' - industry sees structural problems DP
Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141 MT
Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 MT
Guggenheim Adjusts Price Target on Merck to $146 From $144 MT
Wells Fargo Adjusts Price Target on Merck & Company to $140 From $135 MT
Deutsche Bank Adjusts Price Target on Merck & Company to $140 From $135 MT
JPMorgan Chase Adjusts Price Target on Merck to $145 From $140 MT
Goldman Sachs Raises Price Target on Merck & Company to $144 From $139 MT
Leerink Partners Raises Price Target on Merck & Company to $136 From $132 MT
Truist Lifts Price Target on Merck to $143 From $142, Keeps Buy Rating MT
AbbVie raises annual profit forecast on strong Skyrizi sales RE
Jefferies Adjusts Merck & Company Price Target to $150 From $145 MT
Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating MT
Chart Merck & Co., Inc.
More charts
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
130.4 USD
Average target price
141.6 USD
Spread / Average Target
+8.63%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
  5. Merck & Co. Declares Q2 Dividend of $0.69, Payable April 7 to Shareholders of Record March 15
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW